483 Wuhan Biocause Pharmaceutical Development Aug 2018

483 Wuhan Biocause Pharmaceutical Development Aug 2018

Tiara Brown-Crosen FDA$119.00 - Available Now

FDA investigators audited the Wuhan Biocause Pharmaceutical Development - Wuhan, China facility and issued inspectional observations (via FDA 483) on 24 Aug 2018.

Product details

  • Category: Human Drugs
  • Inspection end: 24 Aug 2018
  • Location: Wuhan, China
  • FEI: 3004202226
Add To Cart